Introduction
Tumor necrosis factor receptor 1 (TNF-R1) and related 'death domain' containing molecules form an emerging family of membrane death receptors that transduce apoptotic signals (reviewed in Refs 1 and 2). This family, named the TNF-R superfamily, contains six members including TNF-R1, Fas, DR3, DR4, DR5 and DR6. These receptors harbor an extracellular region with varying numbers of cysteine-rich domains and an intracellular region that contains 'death domain'. The death domain is a stretch of amino acids that shows varying degree of homology among various death receptors and is critical for their apoptotic signal transduction (reviewed in Ref. 2) . The ligands for these receptors also form a family of related cytokines. Named the TNF family, it contains member cytokines such as TNF␣, LT␣, FasL, Apo3L and TRAIL (TNFrelated apoptosis inducing ligand; also known as Apo2L) (reviewed in Ref. 2 ). These ligands function in an autocrine or paracrine manner to mediate their apoptotic effects via their respective cell surface membrane death receptors.
TNF␣ and TNF-R1 ligand/receptor complex
TNF␣ and another ligand LT␣ mediate their effects via TNF-R1 and TNFR2. These ligands bind to both receptors as homo- trimers and induce receptor trimerization; receptor trimerization is necessary for receptor activation (reviewed in Refs 1 and 2). TNFR2 does not contain the intracellular death domain and is generally not implicated in mediating the apoptotic signals. Thus, TNF-R1 is the major receptor responsible for mediating the apoptotic signals of TNF ligand receptor system ( Figure 1 ) (reviewed in Refs 1 and 2). TNF-R1 upon activation recruits the intracellular adaptor molecule TRADD (TNFR-associated death domain protein). TRADD is a death domain containing adaptor molecule 3 that further recruits another death domain containing protein FADD (Fas-associated death domain protein). 4, 5 The interactions among these adaptor molecules and TNF-R1 occur through their respective death domains leaving free the N-terminal death effector domain of FADD to further interact with the analogous domain of proximal procaspase 8 or 10 ( In addition to activation of apoptotic axis, TNF-R1 also relays signals that impinge upon cell survival. For example,
Figure 1
TNF/TNF-R1-mediated apoptotic and survival pathways.
TRADD also recruits TRAF1 and TRAF2, the adaptor molecules that lead to activation of JNK (Jun N-terminal kinase) and NF-B (Figure 1) (Figure 1) . 6, 7 More recently, a novel molecule named silencer of death domain (SODD) has been identified. 8 SODD is believed to interact with the death domain of TNF-R1 and keeps the receptor in monomeric form. 8 Upon activation of TNF-R1, SODD dissociates form the receptor, the ensuing oligomerization of receptor results in its activation and consequently the apoptotic signals flow further downstream. 8 Thus, TNF-R1 activation involves complex series of interactions with the intracellular molecules to mediate apoptotic and survival signals.
In general, transcription or proteins synthesis inhibition potentiates TNF-induced apoptosis. Since TNF-R1 activation also results in concomitant activation of anti-apoptotic NF-B, it has been proposed that inhibition of NF-B-mediated effects by transcription and proteins synthesis inhibitors relieve from anti-apoptotic controls and the balance shifts in favor of apoptotic axis. Evidence in favor of this contention includes the NF-B-dependent upregulation of TRAF1, TRAF2, cIAP1 and cIAP2 gene expression. 9 TRAFs have been shown to bind to TNF-R1 and prevent TNF␣-induced activation of caspase 8 at the receptor site while cIAPs inhibit caspase 3 and 7 activation. 9 TRAFs also serve to function in a positive feed back loop to further promote NF-B activation. Thus, transcription and proteins synthesis inhibitors appear to block NF-Binduced survival signals and consequently shift the balance in the favor of apoptotic signals. 11 Evidence suggests that Daxx bridges Fas interactions with ASK1 (also known as MAP3 kinase) which results in subsequent activation of JNK pathway ( Figure 2) . 12 Fas activation of JNK via Daxx and ASK1 is believed to be a second pathway via which Fas mediates its apoptotic signals (Figure 2 ).
FasL and Fas ligand receptor complex

Apo3L and DR3 ligand receptor complex
DR3 is a third member of TNFR family and is activated by its ligand Apo3L. [13] [14] [15] DR3 is identical to TNF-R1 in terms of interactions with intracellular molecules, however, unlike TNF-R1, DR3 expression is restricted to lymphocyte-rich tissues. 13, 14 It is interesting that Apo3L has a broader tissue distribution than its cognate receptor DR3. [13] [14] [15] This finding raises the possibility that Aop3L may also bind to other as of yet unidentified receptor(s) and/or functions predominantly in a paracrine manner.
TRAIL and DR4/DR5 ligand receptor complex
As the name indicates, DR4 and DR5 are the fourth and fifth members of TNFR superfamily. Both DR4 and DR5 have been identified only recently and bind to their physiological ligand TRAIL (reviewed in Refs 2 and 16). Evidence suggests that both DR4 and DR5 appear to mediate their apoptotic signals in a manner similar to other family members but the adaptor molecule(s) that bridge their interactions with the intracellular proximal caspases has/have not been identified (reviewed in Refs 2 and 16). There has been some controversy regarding FADD being a molecule that bridges their interactions with the proximal caspases. The controversy may stem from differences in the experimental systems used by different investigators. However, cells from FADD-deficient animals were proficient in DR4-mediated apoptosis 17 suggesting that FADD may not be essential for the apoptotic effects of these death receptors. Evidence suggests that both of these receptors can also activate NF-B and JNK pathways.
18,19
DR6
The sixth member in the TNFR family, DR6, is unusual in that it contains a eucine-zipper-like motif in its cytoplasmic region. 20 The leucine-zipper-like motif overlaps with a proline-rich motif that is believed to interact with src-homology-3 (SH3) domains. Although the ligand for DR6 has not been identified, its overexpression has been shown to induce apoptosis and activation of NF-B and JNK pathways. 20 Available evidence suggests that DR6 appears to mediate apoptosis in a TRADD-dependent but FADD-independent manner. 20 The issue as to how DR6 talks to proximal caspases and the downstream caspase cascade remains unclear and requires further investigation.
Decoy members of the TNFR family
In addition to death receptors, four decoy molecules that belong to the TNFR family have also been identified. DcR1 (also known as TRID or TRAIL-R3) [21] [22] [23] and DcR2 (also known as TRUNDD or TRAIL-R4) [24] [25] [26] are cell surface proteins whereas DcR3 27 and OPG (osteoprotegrin) 28 are soluble molecules. Both DcR1/TRID and DcR2/TRUNDD bind to TRAIL with a similar affinity, as do DR4 and DR5. DcR1/TRID is a GPI (glycosylphosphatidylinositol)-linked protein devoid of intracellular death domain whereas DcR2/TRUNDD is a transmembrane receptor with a partially deleted death domain and accordingly, both are unable to transduce apoptotic signals (reviewed in Refs 2 and 16). OPG is a secreted protein that also binds to TRAIL but with much less affinity than the other receptors. 28 DcR3 is closely related to OPG and like OPG, DcR3 is also a secreted protein. DcR3 binds to Fas in a manner similar to FasL and thus, blocks FasL/Fas-mediated apoptosis.
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Death and decoy receptor regulation during p53-mediated apoptosis p53 is one of the most frequently mutated tumor suppressor genes. Abnormalities in p53 have been implicated in a variety of human cancers. The p53 protein is believed to play roles in various different cellular processes but is most extensively studied for its roles in growth arrest and apoptosis (reviewed in Refs 29-33). Despite the fact that p53 has been known for a long time and the fact that its role in apoptosis is undisputed, the exact mechanism(s) via which p53 mediates apoptosis remain less well understood. p53 functions as a transcription factor to modulate the expression of its downstream effector genes (reviewed in Refs 29-33). p53 transcriptionally induces the expression of a variety of genes whose products are believed to control apoptosis (reviewed in Refs 31 and 33). Evidence suggests that p53 also appears to induce apoptosis in a transcription-independent manner (Refs 34 and 35 and reviewed in Refs 29, 31 and 33). Transcription-dependent and -independent apoptotic functions of p53 may vary with the cell type and apoptotic insult.
Recent studies suggest that the TNF ligand/receptor family members may also contribute to p53-mediated apoptotic signaling pathways. p53 has been shown to induce the expression of FAS, [36] [37] [38] 30 and 31) . Evidence suggests that FASL is also regulated by genotoxic Leukemia stress in a p53-dependent manner in some systems. 36, 43 Further studies are needed to determine whether FASL is a direct target of p53. It is possible that p53-mediated upregulation of Fas and DR5 may engage the intracellular caspase cascade to induce apoptosis (Figure 3) . Although p53 may not regulate DR5 ligand TRAIL, it may either induce both FasL and Fas or only Fas to activate the apoptotic signals emanating from this death receptor (Figure 3) . A recent study has demonstrated that p53 appears also to activate Fas by increasing the translocation of Fas through Golgi to the cell surface. 44 Evidence, however, suggests that p53 may not absolutely require the FasL/Fas system to mediate its apoptotic effects. 45, 46 In the case of DR5, p53 does not seem to regulate the expression of its ligand TRAIL. However, overexpression of DR5 has been shown to induce apoptosis in a ligand-independent manner. It is therefore possible that p53 by upregulating the levels of DR5 may activate DR5 in a ligand-independent manner (Figure 3) . The requirement of DR5 during p53-mediated apoptosis remains unclear. Given the multifaceted nature of p53-mediated apoptotic effects, p53 may not display an absolute requirement for DR5. Nevertheless, the generation of DR5-deficient mice and cells might help in addressing some of these issues.
p53 has also been shown to induce the expression of DcR1/TRID 41, 42 and DCR2/TRUNDD. 42 However, it is not clear whether p53 directly upregulates the expression of these genes. Furthermore, the significance of their upregulation by p53 also remains unclear. p53-mediated induction of these genes occurs prior to (within 6 h) p53-induced growth arrest or apoptosis suggesting that DcR1/TRID and DcR2/TRUNDD upregulation is not the consequence of p53-induced growth arrest. 4, 42 DcR2/TRUNDD overexpression has recently been shown to partially protect from p53 and DR5-mediated apoptosis. 42 The intracellular domain of DcR2/TRUNDD appears to be required for its protective effects against p53 and DR5 but not against TRAIL-induced apoptosis.
42 DR4, DR5, DcR1/TRID and DcR2/TRUNDD are highly homologous genes and reside, as a cluster, on chromosome 8p21; it is possible that they may have arisen due to duplication of a common ancestor gene. If this is true, these genes could contain conserved regulatory elements including perhaps p53 response sites. Future studies aimed at promoter characterization of these genes should provide clues to their regulation by p53.
DcR1/TRID and DcR2/TRUNDD are anti-apoptotic decoy receptors that compete with DR4 and DR5 for TRAIL binding and thus protect from TRAIL-induced apoptosis (reviewed in Refs 2 and 16). The significance of their upregulation by p53 remains unclear. p53 appears to activate DR5 to mediate apoptosis, it is thus possible that p53 by regulating the decoy receptors may blunt DR5-dependent apoptosis and consequently control its own apoptotic effects. The ability of decoy receptors to function in a negative feed back loop and thereby allowing p53 to control its own apoptotic effects is not without precedence. Mdm2 is a well known example of a molecule that functions in a negative feed back loop to control the effects of p53. p53 also upregulates the expression of proapoptotic Bax 47 and anti-apoptotic Bcl-X L . 48 It is well known that Bcl-X L tends to disrupt the Bax:Bax homodimers to mediate its anti-apoptotic effects (reviewed in Ref. 49 ). It is thus, possible that p53 may also blunt its Bax-dependent apoptotic effects by regulating the expression of Bcl-X L . DcR1/TRID is a GPI-linked protein and its potential in active signal transduction has not been investigated. Evidence suggests that DcR2/TRUNDD may be involved in active signal transduction since it has been shown to activate NF-B pathway. 25 However, there are reports suggesting the inability of DcR2/TRUNDD to activate NF-B in some systems (Ref. 42 and references therein). Thus, more in-depth studies are needed to explore the potential of DcR1/TRID and DcR2/TRUNDD in anti-apoptotic signal transduction and their role in affecting p53-mediated apoptosis.
